In which clinical situations should I choose Rexulti (brexpiprazole) over Vraylar (cariprazine) for treating schizophrenia, bipolar I disorder, or major depressive disorder?

Rexulti (Brexpiprazole) vs Vraylar (Cariprazine): Clinical Selection Guide

Choose Vraylar (cariprazine) over Rexulti (brexpiprazole) for most patients with schizophrenia, bipolar mania, or treatment-resistant depression based on superior efficacy outcomes, particularly for negative symptoms in schizophrenia and disability reduction in depression. However, select Rexulti when extrapyramidal side effects (EPS) are a primary concern or when treating agitation in dementia.

Schizophrenia

For acute schizophrenia, prefer Vraylar as it demonstrates efficacy against both positive and negative symptoms. The 2025 INTEGRATE guidelines 1 specifically mention cariprazine as a first-line option when considering D2 partial agonists, noting that if first-line treatment with a D2 partial agonist fails, switching to amisulpride, risperidone, paliperidone, or olanzapine should be considered—suggesting cariprazine's distinct pharmacological profile.

Key Differentiators:

• Vraylar: Effective for primary negative symptoms of schizophrenia 2, which is a unique advantage. Dose range 1.5-6 mg daily 3
• Rexulti: Comparable acute antipsychotic efficacy but less evidence for negative symptoms 2
• EPS Risk: Both carry akathisia risk, but cariprazine shows higher rates compared to some other SGAs 4. If akathisia is a major concern, brexpiprazole may be slightly better tolerated

Bipolar I Disorder

For bipolar mania, choose Vraylar as it has FDA approval and demonstrated antimanic efficacy 32. Vraylar is also approved for bipolar depression in adults 3, making it more versatile across bipolar spectrum.

Clinical Algorithm:

• Manic/mixed episodes: Vraylar 3-6 mg daily 3
• Bipolar depression: Vraylar (FDA-approved) 3
• Relapse prevention: Neither has strong evidence; consider alternatives

Rexulti lacks FDA approval for any bipolar indication 2, making it an off-label choice.

Major Depressive Disorder (Adjunctive Treatment)

For treatment-resistant depression, Vraylar demonstrates superior real-world outcomes despite both drugs being FDA-approved for adjunctive MDD treatment.

Evidence Hierarchy:

Most compelling data (2025): Real-world analysis showed cariprazine produced significantly greater reductions versus brexpiprazole in 5:

• All-cause disability claims: -0.23 claims (P<0.05)
• All-cause disability days: -25.27 days (P<0.001)
• All-cause disability costs: -$4,577 (P<0.01)
• Mental health disability days: -12.07 days (P<0.05)

Dose-response meta-analysis (2024) 6 found:

• Maximum effective doses: Aripiprazole 5.5 mg > Brexpiprazole 1.6 mg > Cariprazine 1.5 mg
• Aripiprazole 5.5-12.5 mg significantly more effective than brexpiprazole 0.5 mg and all cariprazine doses
• Brexpiprazole 1-3 mg more effective than cariprazine 0.5 mg

Practical Selection:

• First choice: Consider aripiprazole (not listed in your question but superior efficacy)
• Between Rexulti and Vraylar: Choose Vraylar for better disability outcomes 5, particularly if functional impairment is prominent
• Choose Rexulti: If patient cannot tolerate higher EPS risk or needs lower effective dosing (1.6 mg vs 1.5 mg maximum effective doses are similar) 6

Side Effect Profiles

Metabolic Effects:

• Both succeeded in limiting metabolic side effects compared to older SGAs 4
• Brexpiprazole: Weight gain during acute treatment remains a concern 4
• Cariprazine: Better metabolic profile but requires effective contraception in women of childbearing age 1

Extrapyramidal Symptoms:

• Both carry akathisia risk higher than placebo 4
• Cariprazine: Higher akathisia risk compared to quetiapine, aripiprazole, ziprasidone 4
• Common EPS with Vraylar: Extrapyramidal symptoms ≥5% in schizophrenia trials 33

Other Considerations:

• Somnolence: Vraylar 7-11% vs placebo 4-6% across indications 3
• Late-occurring adverse reactions: Vraylar has specific warning due to long half-life 3
• Mitochondrial toxicity: Both drugs inhibit respiratory complex I 7, though clinical significance for movement disorders unclear

Critical Caveats

Vraylar-Specific Warnings:

• Long half-life means effects/side effects may take weeks to fully manifest or resolve 3
• Contraception required in women of childbearing potential 1
• Monitor for late-occurring adverse reactions 3

When to Avoid Both:

• Elderly patients with dementia-related psychosis (black box warning) 33
• High fall risk (both increase fall risk) 33

Algorithm Summary

1. Schizophrenia with negative symptoms: Vraylar
2. Schizophrenia with high EPS sensitivity: Rexulti (marginally)
3. Bipolar mania or bipolar depression: Vraylar (FDA-approved)
4. Treatment-resistant depression with disability: Vraylar (superior real-world outcomes) 5
5. Treatment-resistant depression with EPS concerns: Rexulti
6. Agitation in dementia: Rexulti (has evidence, though off-label) 2

The 2023 ACP guideline 8 emphasizes that benefits appear similar among antidepressant augmentation strategies with low certainty of evidence, reinforcing the importance of adverse event profiles and patient preferences—making Vraylar's superior disability outcomes 5 particularly valuable for clinical decision-making.